Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 54 of the 56 references it cites were found in a registry or an index; 13 of the 29 sources its claims cite were checked for support.

Antidepressants for the treatment of adults with major depressive disorder in the maintenance phase: a systematic review and network meta-analysis

Open access

Abstract

A systematic review and random-effects model network meta-analysis were conducted to compare the efficacy, acceptability, tolerability, and safety of antidepressants to treat adults with major depressive disorder (MDD) in the maintenance phase. This study searched the PubMed, Cochrane Library, and Embase databases and included only double-blind, randomized, placebo-controlled trials with an enrichment design: patients were stabilized on the antidepressant of interest during the open-label study and then randomized to receive the same antidepressant or placebo. The outcomes were the 6-month relapse rate (primary outcome, efficacy), all-cause discontinuation (acceptability), discontinuation due to adverse events (tolerability), and the incidence of individual adverse events. The risk ratio with a 95% credible interval was calculated. The meta-analysis comprised 34 studies (n = 9384, mean age = 43.80 years, and %females = 68.10%) on 20 antidepressants (agomelatine, amitriptyline, bupropion, citalopram, desvenlafaxine, duloxetine, escitalopram, fluoxetine, fluvoxamine, levomilnacipran, milnacipran, mirtazapine, nefazodone, paroxetine, reboxetine, sertraline, tianeptine, venlafaxine, vilazodone, and vortioxetine) and a placebo. In terms of the 6-month relapse rate, amitriptyline, citalopram, desvenlafaxine, duloxetine, fluoxetine, fluvoxamine, mirtazapine, nefazodone, paroxetine, reboxetine, sertraline, tianeptine, venlafaxine, and vortioxetine outperformed placebo. Compared to placebo, desvenlafaxine, paroxetine, sertraline, venlafaxine, and vortioxetine had lower all-cause discontinuation; however, sertraline had a higher discontinuation rate due to adverse events. Compared to placebo, venlafaxine was associated with a lower incidence of dizziness, while desvenlafaxine, sertraline, and vortioxetine were associated with a higher incidence of nausea/vomiting. In conclusion, desvenlafaxine, paroxetine, venlafaxine, and vortioxetine had reasonable efficacy, acceptability, and tolerability in the treatment of adults with stable MDD.

Overview

CoChat Summary

TL;DR

This systematic review and Bayesian network meta-analysis compared 20 antidepressants with placebo for maintenance treatment of adults with major depressive disorder, using double-blind randomized placebo-controlled trials with an enrichment design. Desvenlafaxine, paroxetine, venlafaxine, and vortioxetine had the best balance of efficacy, acceptability, and tolerability, though desvenlafaxine and vortioxetine carried a higher risk of nausea/vomiting.

Key findings

  • The analysis included 34 double-blind randomized placebo-controlled trials with an enrichment design (n = 9,384; mean age = 43.80 years; 68.10% females) covering 20 antidepressants plus placebo.
  • For the 6-month relapse rate, amitriptyline, citalopram, desvenlafaxine, duloxetine, fluoxetine, fluvoxamine, mirtazapine, nefazodone, paroxetine, reboxetine, sertraline, tianeptine, venlafaxine, and vortioxetine outperformed placebo, with risk ratios ranging from 0.149 (95% CrI 0.018–0.610) for nefazodone to 0.583 (95% CrI 0.410–0.789) for fluoxetine.
  • Compared with placebo, desvenlafaxine, paroxetine, sertraline, venlafaxine, and vortioxetine had lower all-cause discontinuation, with risk ratios ranging from 0.523 (95% CrI 0.327–0.817) for paroxetine to 0.768 (95% CrI 0.518–0.998) for vortioxetine.
  • Sertraline was associated with a higher rate of discontinuation due to adverse events; desvenlafaxine, sertraline, and vortioxetine were associated with higher nausea/vomiting, while venlafaxine was associated with lower dizziness.

Methods

  • Systematic review and random-effects Bayesian network meta-analysis of double-blind, randomized, placebo-controlled trials with an enrichment design and minimum 12-week duration; patients were stabilized on the antidepressant of interest during open-label treatment and then randomized to the same antidepressant or placebo.
  • Searched PubMed, Cochrane Library, and Embase; included 34 studies (n = 9,384) on 20 antidepressants and placebo. Outcomes were 6-month relapse rate (primary), all-cause discontinuation, discontinuation due to adverse events, and individual adverse events.
  • Calculated risk ratios with 95% credible intervals; also performed pairwise meta-analyses, heterogeneity assessment, transitivity testing, meta-regression, ROB2 quality assessment, and CINeMA grading.

Limitations

  • Stated: the number of participants and trials for some antidepressants, especially tricyclics, was small, and some results were based on only one study; the study did not cover important clinical issues such as monotherapy versus combination with nonpharmacological treatments, and did not include some side effects such as agitation due to lack of data.
  • Stated: because no double-blind randomized placebo-controlled trials with an enrichment design existed for treatments such as lithium or psychotherapy, those treatments were not evaluated.
  • Evident from the text: no head-to-head studies compared different antidepressants, so statistical incoherence could not be evaluated; publication bias was rated “suspected” for all comparisons because funnel plots had fewer than 10 studies; confidence in the evidence for the primary outcome was “very low” for all comparisons except vortioxetine versus placebo, which was “low”; 31 of 34 studies were industry-sponsored.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1038/s41380-022-01824-z

Cites

54 of 54 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 Forest plots for the 6-month relapse and all-cause discontinuation rates. A 6-month relapse rate and B all-cause discontinuation rate. Medications were compared to a placebo. Colors indicate the presence or absence of a statistically significant difference, with blue indicating that the drug was superior to the placebo and black indicating that the drug was comparable to the placebo. 95% CrI 95% credible interval, AGO agomelatine, AMI amitriptyline, BUP bupropion, CIT citalopram, DES desvenlafaxine, DUL duloxetine, ESC escitalopram, FLUO fluoxetine, FLUV fluvoxamine, LEV levomilnacipran, MIL milnacipran, MIR mirtazapine, NEF nefazodone, PAR paroxetine, REB reboxetine, RR risk ratio, SER sertraline, TIA tianeptine, VEN venlafaxine, VIL vilazodone, VOR vortioxetine.
Fig. 1 Forest plots for the 6-month relapse and all-cause discontinuation rates. A 6-month relapse rate and B all-cause discontinuation rate. Medications were compared to a placebo. Colors indicate the presence or absence of a statistically significant difference, with blue indicating that the drug was superior to the placebo and black indicating that the drug was comparable to the placebo. 95% CrI 95% credible interval, AGO agomelatine, AMI amitriptyline, BUP bupropion, CIT citalopram, DES desvenlafaxine, DUL duloxetine, ESC escitalopram, FLUO fluoxetine, FLUV fluvoxamine, LEV levomilnacipran, MIL milnacipran, MIR mirtazapine, NEF nefazodone, PAR paroxetine, REB reboxetine, RR risk ratio, SER sertraline, TIA tianeptine, VEN venlafaxine, VIL vilazodone, VOR vortioxetine.CC BY · PubMed Central
Fig. 2 Forest plots for discontinuation rate due to adverse events and nausea/vomiting. A Discontinuation rate due to adverse events and B nausea/vomiting. Medications were compared with a placebo. Colors indicate the presence or absence of a statistically significant difference, with red indicating that the drug was inferior to the placebo and black indicating that the drug was comparable to the placebo. 95% CrI 95% credible interval, AGO agomelatine, BUP bupropion, CIT citalopram, DES desvenlafaxine, DUL duloxetine, ESC escitalopram, FLUO fluoxetine, FLUV fluvoxamine, LEV levomilnacipran, MIR mirtazapine, NEF nefazodone, PAR paroxetine, REB reboxetine, RR risk ratio, SER sertraline, VEN venlafaxine, VIL vilazodone, VOR vortioxetine.
Fig. 2 Forest plots for discontinuation rate due to adverse events and nausea/vomiting. A Discontinuation rate due to adverse events and B nausea/vomiting. Medications were compared with a placebo. Colors indicate the presence or absence of a statistically significant difference, with red indicating that the drug was inferior to the placebo and black indicating that the drug was comparable to the placebo. 95% CrI 95% credible interval, AGO agomelatine, BUP bupropion, CIT citalopram, DES desvenlafaxine, DUL duloxetine, ESC escitalopram, FLUO fluoxetine, FLUV fluvoxamine, LEV levomilnacipran, MIR mirtazapine, NEF nefazodone, PAR paroxetine, REB reboxetine, RR risk ratio, SER sertraline, VEN venlafaxine, VIL vilazodone, VOR vortioxetine.CC BY · PubMed Central

Verification

Claims the paper makes

9 Valid · 1 Not valid · 8 Not checked · 49 Own results and interpretations

25 more claims

Create a free account to see all 67 claims and every source verdict.

See all claims — free account
  • It may state two separate claims as one. 20
  • Probably not a substantial claim. 23
  • The quote only partly states this claim. 3

Create a free account to see these claims.

Citations

Cites

Show all 56 references

Research works printed but not linked: 2

  1. Baldessarin IR Chemotherapy in Psychiatry, 3rd edition. Springer Press 2013; New York.
  2. Dekker J, Jonghe F, Tuynman H. The use of anti-depressants after recovery from depression. Eur J Psychiatry. 2000;14:207–12.

Cited by

See all 136

Metadata

Authors
Kishi, T., Ikuta, T., Sakuma, K., Okuya, M., Hatano, M., Matsuda, Y., & Iwata, N.
Affiliations
  • Fujita Health University (JP)
  • University of Mississippi (US)
  • Jikei University School of Medicine (JP)
Corresponding author
Kishi, Taro
Venue
Molecular Psychiatry
Published
2022-10-17
Volume
28
Issue
1
Pages
402-409
ISSN
  • 1359-4184 (ISSN-L)
  • 1476-5578
OpenAlex
W4306404458
Cited by
136
References
56
Citations by year
2026: 34 · 2025: 41 · 2024: 39 · 2023: 21 · 2022: 1
FWCI
3.66
Type
journal article
Language
en
Open access
Licence
Locations
  • Molecular Psychiatry (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
  • Eli Lilly and Company
  • Japan Agency for Medical Research and Development
  • Kissei
  • Eisai
  • Shionogi
  • Fujita Health University
  • Kansai Medical University
  • Japan Society for the Promotion of Science (21K15738)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
  • Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
Keywords
antidepressants, major depressive disorder, maintenance therapy, relapse prevention, relapse rate, treatment discontinuation, adverse events, dizziness, nausea, venlafaxine, desvenlafaxine, paroxetine, vortioxetine, sertraline, agomelatine, mirtazapine, bupropion
MeSH terms
Duloxetine Hydrochloride, Desvenlafaxine Succinate, Venlafaxine Hydrochloride, Reboxetine, Vortioxetine, Mirtazapine, Adult, Amitriptyline, Antidepressive Agents, Major Depressive Disorder, Female, Fluoxetine, Humans, Thiazepines, Citalopram, Randomized Controlled Trials as Topic, Fluvoxamine, Paroxetine, Sertraline

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Antidepressants for the treatment of adults with major depressive disorder in the maintenance phase: a systematic review and network meta-analysis. https://app.cochat.ai/papers/10.1038/s41380-022-01824-z
The paper
Kishi, T., Ikuta, T., Sakuma, K., Okuya, M., Hatano, M., Matsuda, Y., & Iwata, N. (2023). Antidepressants for the treatment of adults with major depressive disorder in the maintenance phase: a systematic review and network meta-analysis. Molecular Psychiatry. https://doi.org/10.1038/s41380-022-01824-z

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.